Validation of the line-probe assay for rapid detection of rifampicin-resistant Mycobacterium tuberculosis in Vietnam

International Journal of Tuberculosis and Lung Disease

Volumn 13, Issue 2, 2009, Pages 247-252

  Shah, N Sarita ^a,b   Lan, N T N ^c   Huyen, M N T ^c   Laserson, K ^a   Iademarco, M F ^a   Binkin, N ^a   Wells, C ^a   Varma, J K ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c Pham Ngoc Thach Hospital   (Viet Nam)

Author keywords

Mycobacterium tuberculosis; Rifampicin resistance; rpoB

Indexed keywords

ISONIAZID; RIFAMPICIN;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG RESISTANT TUBERCULOSIS; DRUG SENSITIVITY; FALSE NEGATIVE RESULT; GENE MUTATION; GENE SEQUENCE; HUMAN; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY; VIET NAM;

ANTIBIOTICS, ANTITUBERCULAR; BACTERIAL PROTEINS; BIOLOGICAL ASSAY; DRUG RESISTANCE, BACTERIAL; HUMANS; LIKELIHOOD FUNCTIONS; MICROBIAL SENSITIVITY TESTS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; POLYMERASE CHAIN REACTION; RIFAMPIN; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS, MULTIDRUG-RESISTANT; VIETNAM;

EID: 59649110513     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. World Health Organization. Anti-tuberculosis drug resistance in the world. Report no 3. WHO/HTM/TB/2004.343. Geneva, Switzerland: WHO, 2004.
2. World Health Organization. Anti-tuberculosis drug resistance in the world. Report no 4. WHO/HTM/TB/2008.394. Geneva, Switzerland: WHO, 2008.
3. Yagui M, Perales M T, Asencios L, et al. Timely diagnosis of MDR-TB under program conditions: is rapid drug susceptibility testing sufficient? Int J Tuberc Lung Dis 2006; 10: 838-843.
4. Shah N S, Wright A, Bai G H, et al. Worldwide emergence of extensively drug-resistant tuberculosis (XDR-TB): global survey of second-line drug resistance among Mycobacterium tuberculosis isolates. Emerg Infect Dis 2007; 13: 380-387.
5. Gandhi N R, Moll A, Sturm A W, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368: 1575-1580.
6. Leimane V. MDR-TB and XDR-TB management in Latvia. Global XDR-TB Task Force meeting, Geneva, Switzerland, 9-10 October 2006. Geneva, Switzerland: WHO, 2006.
7. Wells C, Cegielski J P, Nelson L, et al. HIV infection and multi-drug-resistant tuberculosis - the perfect storm. J Infect Dis 2007; 196 (Suppl): S86-S107.
8. Shah N S, Pratt R, Robison V, Cegielski J P. Extensively drug-resistant tuberculosis (XDR-TB) in the United States, 1993-2004. National Tuberculosis Controllers' meeting, 2006. Atlanta, GA, USA: National Tuberculosis Controllers' Association, 2006.
9. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: emergency update. 2008. Geneva, Switzerland: WHO, 2008.
10. World Health Organization. Report of the meeting of the Global XDR TB Task Force. WHO/HTM/TB/2007.374. Geneva, Switzerland: WHO, 2006. http://whqlibdoc.who.int/hq/2007/who_htm_tb_2007.375_eng.pdf Accessed November 2008.
11. Pai M, Kalantari S, Dheda K. New tools and emerging technologies for the diagnosis of tuberculosis: Part II. Active tuberculosis and drug resistance. Expert Rev Mol Diagn 2006; 6: 423-432.
12. Sekiguchi J, Miyoshi-Akiyama T, Ugustynowicz-Kopec E, et al. Detection of multidrug resistance in Mycobacterium tuberculosis. J Clin Microbiol 2007; 45: 179-192.
13. Hillemann D, Weizenegger M, Kubica T, Richter E, Niemann S. Use of the genotype MTBDR assay for rapid detection of rifampicin and isoniazid resistance in Mycobacterium tuberculosis complex isolates. J Clin Microbiol 2005; 43: 3699-3703.
14. Barnard M, Albert H, Coetzee G, O'Brien R, Bosman M E. Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am J Respir Crit Care Med 2008; 177: 787-792.
15. Kocagoz T, Saribas Z, Alp A. Rapid determination of rifampicin resistance in clinical isolates of Mycobacterium tuberculosis by real-time PCR. J Clin Microbiol 2005; 43: 6015-6019.
16. Cooksey R C, Morlock G P, Glickman S, Crawford J T. Evaluation of a line-probe assay kit for characterization of rpoB mutations in rifampicin-resistant Mycobacterium tuberculosis isolates from New York City. J Clin Microbiol 1997; 35: 1281-1283.
17. Hirano K, Abe C, Takahashi M. Mutations in the rpoB gene of rifampicin-resistant Mycobacterium tuberculosis strains isolated mostly in Asian countries and their rapid detection by line-probe assay. J Clin Microbiol 1999; 37: 2663-2666.
18. Johansen I S, Lundgren B, Sosnovskaja A, Thomsen V O. Direct detection of multidrug-resistant Mycobacterium tuberculosis in clinical specimens in low- and high-incidence countries by line-probe assay. J Clin Microbiol 2003; 41: 4454-4456.
19. Traore H, Fissette K, Bastian I, Devleeschouwer M, Portaels F. Detection of rifampicin resistance in Mycobacterium tuberculosis isolates from diverse countries by a commercial line-probe assay as an initial indicator of multidrug resistance. Int J Tuberc Lung Dis 2000; 4: 481-484.
20. Rossau R, Traore H, De B H et al. Evaluation of the INNO-LiPA Rif. TB assay, a reverse hybridization assay for the simultaneous detection of Mycobacterium tuberculosis complex and its resistance to rifampicin. Antimicrob Agents Chemother 1997; 41: 2093-2098.
21. Caws M, Duy P M, Tho D Q, Lan N T, Hoa D V, Farrar J. Mutations prevalent among rifampicin- and isoniazid-resistant Mycobacterium tuberculosis isolates from a hospital in Vietnam. J Clin Microbiol 2006; 44: 2333-2337.
22. Huong N T, Lan N T, Cobelens F G, et al. Anti-tuberculosis drug resistance in the south of Vietnam: prevalence and trends. J Infect Dis 2006; 194: 1226-1232.
23. National Committee on Clinical Laboratory Standards. Susceptibility testing of mycobacteria, nocardiae and other aerobic actinomycetes. Approved standard. NCCLS document M24-A. Wayne, PA, USA: NCCLS, 2003.
24. Grimes D A, Schulz K F. Refining clinical diagnosis with likelihood ratios. Lancet 2005; 365: 1500-1505.
25. Grandjean L, Moore D A. Tuberculosis in the developing world: recent advances in diagnosis with special consideration of extensively drug-resistant tuberculosis. Curr Opin Infect Dis 2008; 21: 454-461.
26. Cuna-Villaorduna C, Vassall A, Henostroza G, et al. Cost-effectiveness analysis of introduction of rapid, alternative methods to identify multidrug-resistant tuberculosis in middle-income countries. Clin Infect Dis 2008; 47: 487-495.
27. Hillemann D, Kubica T, Rusch-Gerdes S, Niemann S. Disequilibrium in distribution of resistance mutations among Mycobacterium tuberculosis Beijing and non-Beijing strains isolated from patients in Germany. Antimicrob Agents Chemother 2005; 49: 1229-1231.
28. Reid A, Scano F, Getahun H, et al. Towards universal access to HIV prevention, treatment, care and support: the role of tuberculosis/HIV collaboration. Lancet Infect Dis 2006; 6: 483-495.